Doxycycline topical Pregnancy and Breastfeeding Warnings
Brand names: Atridox
Doxycycline topical Pregnancy Warnings
Doxycycline topical has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryo- and fetotoxicity, including toxic effects on skeletal formation. There are no controlled data in human pregnancies. However, congenital defects have been reported with the class of tetracyclines. Fetal effects may be dose-related. When used during tooth development (second half of pregnancy) tetracyclines may cause permanent yellow-gray-brown discoloration of the teeth and enamel hypoplasia. Doxycycline topical is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.
Doxycycline topical Breastfeeding Warnings
Doxycycline is excreted into human milk. Theoretical risks of dental staining and inhibition of bone growth exist although they are unlikely. Tetracycline, a related drug, is considered compatible with breast-feeding by the American Academy of Pediatrics. However, the manufacturer recommends that due to the potential for adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See also
References for pregnancy information
- Product Information. Atridox (doxycycline topical). Block Drug Company. 2001;PROD.
References for breastfeeding information
- Roberts RJ, Blumer JL, Gorman RL, et al. American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk. Pediatrics. 1989;84:924-36.
- Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. Baltimore, MD: Williams & Wilkins. 1998.
- Product Information. Atridox (doxycycline topical). Block Drug Company. 2001;PROD.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
